Uncategorized

Theravance, after clinical setbacks, agrees to $929M buyout

Published

on

The acquisition by royalty management company Zymeworks follows a “strategic review” triggered by the failure of a drug for a type of low blood pressure.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version